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Abstract
I In nt tr ro od du uc ct ti io on n: :   Management of haemophilia and inherited bleeding disorders is
a major challenge especially in developing countries, because of a shortage or
absence  of  products,  the  cost  and  the  infrastructural  health  problems.
Development of local expertise which results in an improved outlook and
reduction in mortality and morbidity in these countries can be helpful for
advocators in other developing countries. However, very little information on
demography and organizational models for haemophilia care in developing
countries are available in the literature. Our aim is a comprehensive report of
haemophilia status and its management in Iran.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The Management Center of Transplantation and Special
Diseases (MCTSD) of the Ministry of Health of Iran decided to carry out a complete
review and compilation of all of the published or available data about patients
with haemophilia (PWH) in Iran: their health status, their management planning,
organizations, treatment products, facilities and care problems during 2007.
R Re es su ul lt ts s: :      6496 patients with congenital bleeding disorders were registered. Most
of them had haemophilia A and B and von Willebrand disease (vWD). However,
rare bleeding disorders are seen more than expected. Inhibitor development is
14-28%. There are different data about virological status of PWH. Factor products
and facilities are fairly available with more than 1.5 units per capita of inhabitant
factor consumption. 
C Co on nc cl lu us si io on ns s: :   A national formulary based on facilities of the country should be
considered and followed by collaboration among the Ministry Of Health,
universities and non-governmental organizations.
K Ke ey y   w wo or rd ds s: :   Iran, haemophilia care, developing world.
Introduction
New advances in haemophilia treatment such as virally safe factor
concentrates and a comprehensive approach to patients have improved
the life expectancy as well as the quality of life for haemophiliacs, especially
in the last 3 decades [1, 2]. However, treatment options vary around the
world. There is wide variability not only in the types of products used
(plasma,  cryoprecipitate,  plasma  derived  factor  concentrates  and
recombinant factor concentrates) but also in the doses administered
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(minimal to very high) for similar indications [3-5].
In developed countries, accurate diagnosis and
treatment based on early recognition of the disease,
carrier detection, antenatal diagnosis, standard
treatment,  prophylaxis,  home  therapy,  early
treatment  of  bleeding  episodes,  sustained
replacement therapy with virally safe clotting factor
concentrates, and establishment of comprehensive
care centres with a multidisciplinary team resulted
in significant effects on patients’ general health,
quality of life and survival. Also the haemophilia
community request resulted in receipt of support
for networks of haemophilia treatment centres
(HTCs) from governments [6, 7].
At the same time, in the developing world (with
almost 80% of the haemophilia population, who
benefit  from  only  20%  of  the  world’s  total
haemophilia care budget), development of local
expertise resulted in an improved outlook and
reduction in mortality and morbidity in spite of
a shortage or absence of factor products [8, 9].
However, very little information on demography and
organizational models for haemophilia care in
developing countries, and also on the types of
products being used for factor replacement and the
doses being administered for control or treatment
of bleeding in different countries, are available in
the literature [5, 10-12]. In this study the current
situation  and  the  developed  plan  for  the
“Hemophilia Care Program in Iran” will be reviewed
to document these data in comparison with other
countries.
I Ir ra an ni ia an n   H Ha ae em mo op ph hi il li ia a   S Se er rv vi ic ce es s   O Or rg ga an ni iz za at ti io on n
Iran is a Middle Eastern country comprising 
30 provinces and covering an area of 1.648 million
square  kilometres.  The  population  is  around 
70 million, life expectancy is 69.96 years [13] and
the gross national product (GNP) is reported to be
2767 US$ per capita in 2005 [14].
Haemophilia management in Iran was organized
in Imam Khomeini hospital of Tehran University of
Medical Sciences in the early 1960s, and it has been
the main centre for haemophilia care until now.
Although the Ministry of Health (MOH) has been
the sponsor of management of haemophilia during
the last 40 years, a turning point came in 2001,
when the MOH established official relations with
haemophilia  and  thalassaemia  treatment  and
management programmes in addition to dialysis
and transplantation through the Management
Center of Transplantation and Special Diseases
(MCTSD)  (Figure  1).  The  organization  was
responsible not only for the provision of necessary
products and services through the undersecretary
of Food and Drugs in the Ministry of Health but also
in policy making and strategic planning to achieve
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and  establish  higher  standards  of  treatment.
Throughout 2001-2003, a major function of the
centre was to assess the situation of treatment and
correction of data. Recognizing the importance of
a national haemophilia programme, MCTSD created
a national haemophilia committee, composed of
physicians who were experts in the treatment of
haemophilic patients. As recommended by the
World Federation of Hemophilia (WFH), the mission
of this committee was the introduction of specific
and practical programmes to be used as tools to
further  treatment  of  haemophilia  and  related
disorders [15], which covered sensible dosing and
equitable distribution of resources to gain the
maximum benefit from scarce resources.
In Iran, at present, 41 medical universities are
responsible for implementing different treatment
and prevention programmes of the Ministry of
Health in all the provinces. In each university, one
is to oversee and coordinate affairs of haemophilia,
thalassaemia,  haemodialysis  and  transplanted
patients in different wards which are covered by
that special university and are in direct contact with
the MCTSD. The data gathering for the national
registry is done by these teams for the centre for
administrative issues. Collection of data is the
mandatory tool, and the budget designation is on
the basis of correct information. After 3 years, the
MCTSD with participation of pundits is going to
develop  a “comprehensive  national  database”
which will be offered on-line to all universities 
in 2007. 
There  are  also  several  non-governmental
organizations, engaged in the field of haemophilia
in Iran, such as the Iranian Hemophilia Society, the
Iranian Pediatric Hematology and Oncology Society
(IPHOS), and the Charity Foundation for Special
Diseases.  Haemophilia  care  units  which  are
affiliated to the MOH in Iran in many provinces are
managed with such collaboration among them,
universities’ staffs and hospitals being under the
provision of the MCTSD.
Non-profit organizations play an important role
in  solving  public  problems,  creating  more
competitive environments for securing charitable
support and strengthening public infrastructures.
The  Iranian  Hemophilia  Society  (IHS)  was
established in 1967 by government authorities 
[16, 17]. Their main objectives were social support
and  contribution  in  education  of  haemophilic
patients  (in  face-to-face  classes  or  through
brochures and CDs). They have 21 branches with
100 staffs throughout the country [17]. They have
also developed a patient registry database to collect
information about haemophiliac patients and their
families [18]. They are also committed to improving
patients’ access to treatment facilities and have
constructed a part-time out-patient clinic with
a well equipped coagulation laboratory in Tehran
since 2001.
Material and methods
In this study, the MCTSD of the MOH of Iran,
which has the main responsibility for the treatment
of haemophilia through 41 medical universities and
their related clinics around the country (as the main
and original sources of haemophilia data in Iran),
carried out a complete review and gathered all of
the published or available data about patients with
haemophilia (PWH) in Iran: their health status, their
management planning, organizations, treatment
and care problems during 2007.
Results and Discussion
F Fr re eq qu ue en nc cy y   a an nd d   p pr re ev va al le en nc ce e
There are 6496 cases with congenital bleeding
disorders who were registered by the MOH of Iran
by  December  2006,  so  the  prevalence  was
estimated at about 9.18 per 100,000. Among
them,  there  are  3957  (61%)  FVIII  deficiency
haemophilia A (frequency of severe, moderate
and mild haemophilia A were 47, 33 and 20%
respectively).  The  prevalence  of  registered
congenital  bleeding  disorders  –  including
congenital platelet function abnormalities [19] –
in Iran is shown in Figure 2. Also, regarding the
poor availability of diagnostic facilities in most of
the centres, the majority of registered cases of
von Willebrand Disease (VWD) are symptomatic
with frequent medical therapies (mainly type 3)
[20], and definite classification for most of the
others has not been possible. Although according
to the WFH’s survey, the rate of diagnosis of
persons with haemophilia is directly related to
the economic income of the region, it is worth
noting that the number of detected haemophilia
A and B (~65 cases per million inhabitants) cases
is much higher than expected based on the GNP
of Iran in 2005 (2767$) (Table I) [12, 14, 21].
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I In nh hi ib bi it to or r   d de ev ve el lo op pm me en nt t
Approximately 15-35% of patients with severe
haemophilia  A in  western  countries  develop
inhibitors [22, 23]. The prevalence of inhibitors in
haemophilia A patients in developing countries has
not been studied extensively [24, 25]. In Iran, there
are only two studies considering the prevalence of
inhibitor development in haemophilia A. Sharifian
et al. reported 184 patients with inhibitor out of
1280 HA registered cases in Tehran University of
Medical Sciences (14%); among them 41 cases (3%)
were high responders. Inhibitor developed in 22, 9.4
and  3.5%  of  severe,  moderate  and  mild  HA
respectively [26]. In another study, 100 cases out of
355 patients (28.1%) from six main haemophilia
care centres in the east and south of Iran in 2005
had developed factor VIII inhibitor; among them 
14 cases (4%) were high responders [27]. The MCTSD
is going to establish a routine screening test in all
of the centres by improving their diagnostic facilities.
B Bl lo oo od d- -b bo or rn ne e   i in nf fe ec ct ti io on ns s
Another important issue is virological status in
haemophiliacs. Hepatitis C virus (HCV) is the current
major virological problem in haemophiliac patients.
Since 1995, more careful donor selection and pre-
transfusion screening of blood donors for anti-HCV
has been implemented in all blood banks. According
to unpublished official data of the MCTSD from 
9 medical universities around Iran, 773 out of 3282
cases with all congenital bleeding disorders were
anti-HCV positive. The prevalence of HCV infection
in Iranian haemophilic patients has been reported
from 15.6% in Fars, a southern district of Iran, to
76.7% in North-West Iran in different studies, as
reviewed by Allavian et al. [28]. The prevalence of
HBS-Ag positive cases has been reported in < 1%
(2/277), 2.8% (5/171), 27% (27/101) and 4.9% (4/81)
of patients in different studies [29-32]. The overall
expected  prevalence  of  HCV  Ab  positivity  in
patients with haemophilia in Iran is 21%, which in
comparison  with  some  other  countries  is  low 
[33-37].  During  winter  2006  to  2007,  400
haemophiliacs with HCV infection were treated with
pegylated interferon α alone or in combination with
ribavirin by the MOH [38]. The prevalence of HIV
positive haemophiliac patients has been reported
as 0.36% (1/277), 2.3% (4/176) and 19% (69/368) in
different groups and in different periods of time
[29-31, 39]. 
Q Qu ua al li it ty y   o of f   l li if fe e
The most common symptoms influencing the
quality of life in Iran [40] and other developing
countries are still haemarthrosis, haematomas and
epistaxis  [10-12].  Fortunately,  in  last  decade,
chemical and radioisotopic synovectomy have been
performed successfully in Imam Khomeini Hospital
between 2002 and 2006. Mortazavi et al. performed
66  radioisotopic  synovectomy  procedures  in 
53 patients. It effectively reduced the intra-articular
bleeding rate and factor concentrate use [41].
T Tr re ea at tm me en nt t   a an nd d   d di ia ag gn no os st ti ic c   f fa ac ci il li it ti ie es s
T Tr ra an ns sf fu us si io on n   a an nd d   b bl lo oo od d   b ba an nk k
During the 1960s, Iranian haemophilic patients
were  treated  mainly  with  plasma  supplied  by
commercial agents who relied mostly on paid blood
donors.  After  establishment  of  the  Iranian 
Blood Transfusion Organization (IBTO) in 1974 as
a governmental non-profit organization for cen-
tralized and scientific activities in transfusion,
cryoprecipitate  and  fresh  frozen  plasma  were
available gradually for them [42]. In order to provide
a safe plasma product for them, in addition to strict
donor selection, donated blood underwent serologic
tests for HBV, HCV (since 1995), HIV and syphilis. The
IBTO is now considering implantation of a nucleic
acid test (NAT) system in its screening protocol [42].
In order to supply the Iran pharmaceutical market
with plasma derived products, the IBTO started a toll
fractionation programme in 2004. After verification
of the quality system of Iranian blood collection
centres by the Paul-Ehrlich Institute (as a reputable
EU authority) in 2005, toll fractionation of about
70,000 l of plasma in France and Germany to 300 kg
of IVIG, 10 MIU FVIII, 14 MIU FIX, and 1800 kg
albumin has been established [42, 43].
P Pr ro od du uc ct ts s   a an nd d   p pr ro ot to oc co ol ls s
Over  the  past  2  decades,  MOH  has  been
responsible for the acquisition and distribution of
concentrated factor products in Iran. These products
include plasma derived factor VIII concentrates
(FVIII:  C)  and  factor  IX  concentrates  (FIX:  C),
prothrombin complex (PCC), activated PCC (APCC),
and  recombinant  FVIIa  (and  recently  VWF)
concentrates and subcutaneous desmopressin for
2007 (Figure 3). After establishment of the MCTSD
in  the  early  2000s,  a regular  programme  has
recently been started which planned the acquisition
of concentrated factor as IU per patient per year
and initiated distribution to the various states
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according to the number of patients registered in each
state. Recently anational scientific and cost-effective
formulary has been prepared by the Thalassemia and
Hemophilia Committee of the MCTSD according to
recommendations  of  the  WFH  and  reliable
international references [2, 8, 10, 15, 44, 45].
In  this  manner,  although  the  total  health
expenditure of GDP is 6% [7] in 2006 the budget
designation for importation of coagulating factors
was about 50,000,000 US$ (20% of the whole
subsidy budget of the Ministry of Health) and factor
VIII was supplied at the rate of 1.5 units per capita
of inhabitant (and 2 units per capita of inhabitant
in 2007), in contrast with many other developing
countries. From March 2006 to March 2007, the
reported  consumption  of  factor  concentrates
nationwide was: FVIII: C, 107 500 000 IU; FIX: C, 
17 000 000 IU; APCC 3 250 000 IU; and rFVIIa 
46 800 mg. The total cost of care of patients
including  products,  routine  diagnostics  and
treatment services are paid by the insurance system
and the Ministry of Health in Iran. In one study in
the Fars province of Iran, the factor cost was 99%
of the total cost of care [46], which is high in
comparison with the USA, UK and Italy (72, 29 and
32% respectively) [47, 48].
Although on-demand therapy is the current
treatment strategy in Iran, it seems that it is time
to  shift  from  on-demand  to  a prophylactic
programme or home therapy and better services
and follow-ups by establishing comprehensive care
centres (CCC) all over the country. At the first step,
it would be done as a pilot study in some provinces
which have expert haematologists and CCCs. A trial
programme  for  home  therapies  and  carrier
detection in haemophilia families was set up in
Esfahan Province by the Genetic Department of the
Center for Disease Control of the MOH in January
2007.  It  has  also  been  underway  in  Shiraz
Hemophilia Center since 2004. The last but not the
least valuable step is developing comprehensive
care, followed through education courses for health
care professionals who are in centres in service of
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patients. The guidelines have been published by
the  MCTSD  and  officially  have  been  sent  to
universities to be prepared for them.
Surgical interventions in Iranian patients with
haemophilia  (PWH),  like  many  others  in  the
developing world, are difficult in the setting of
limited availability of factor concentrates on one
hand  and  lack  of  established  international
guidelines for factor concentrate prophylaxis for
PWH undergoing surgery on the other hand. These
recommendations were not established based on
large clinical trials and fail to define the safe lower
limit of factor concentrate prophylaxis for surgery
[4]. Whenever the factor supply is in acceptable
amounts for elective surgery (especially orthopaedic
surgery and circumcision), it is officially announced.
D Di ia ag gn no os si is s   a an nd d   p pr re ev ve en nt ti io on n
Diagnostic facilities have grown up around the
country and now at least 3 well equipped special
coagulation and molecular genetics laboratories
with expert staffs exist in Iran. The current facilities
of the IBTO coagulation laboratory are demon-
strated in Table II. 
Prenatal diagnosis (PND), a young programme, is
an important issue in the comprehensive care of
haemophiliacs. As a consequence of technological
progress made in this field in Iran, especially during
the last 3 years [49], the early detection of an
affected fetus through diagnosis of families with
a diseased child to reduce incidence with a chance
to terminate pregnancy is a young programme in the
country. There are two main limitations in this issue.
The first is that most Iranians were not familiar with
the possibilities afforded by PND for haemophilia
[50]. The second is that although there are some
passed fatwas (a fatwa is a religious opinion about
whether  an  action  is  permissible,  prohibited,
obligatory  or  disliked)  from  religious  scholars
permitting abortion in positive cases, it is not yet
legal. The subject is being followed by the MOH.
In  conclusion,  we  argue  that  treatment  of
haemophiliacs in the developing countries should
be based on at least two aspects. First, a national
formulary based on facilities of the country should
be  considered  and  followed.  As  a result,  the
minimum acceptable standards can be achieved
more easily and the next steps become practical.
Heterogenicity is risky for any strategic planning.
Secondly, cooperation among medical personnel,
the government, NGOs and scientific boards must
be promoted to establish successful care. 
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